A novel trichosanthin fusion protein with increased cytotoxicity to tumor cells

Biotechnol Lett. 2017 Jan;39(1):71-78. doi: 10.1007/s10529-016-2222-0. Epub 2016 Oct 6.

Abstract

Objective: To evaluate the anti-tumor effects of trichosanthin after fusion with a cell penetrating peptide, heparin-binding peptide (HBP), derived from human heparin-binding EGF-like growth factor (HB-EGF).

Results: The fusion protein of trichosanthin-HBP was expressed in Escherichia coli BL21 and purified by Ni-NTA affinity chromatography. The HBP domain had no influence on the topological inactivation activity and N-glycosidase activity of trichosanthin. Trichosanthin-HBP significantly inhibited the growth of tested cancer cells which are impervious to trichosanthin. Tumor cell apoptosis and both the mitochondrial- and death receptor-mediated apoptotic signaling pathways induced by trichosanthin-HBP were more significant than those induced by trichosanthin in HeLa cells.

Conclusion: HBP is an efficient intracellular delivery vehicle for trichosanthin and makes trichosanthin-HBP become a promising agent for cancer therapy.

Keywords: Antitumor activity; Apoptosis; Drug delivery; Heparin-binding EGF-like growth factor; Trichosanthin.

MeSH terms

  • Antineoplastic Agents / metabolism*
  • Antineoplastic Agents / pharmacology*
  • Apoptosis / drug effects
  • HeLa Cells
  • Heparin-binding EGF-like Growth Factor / chemistry*
  • Humans
  • Peptides / genetics
  • Peptides / metabolism*
  • Peptides / pharmacology*
  • Recombinant Fusion Proteins / genetics
  • Recombinant Fusion Proteins / metabolism*
  • Recombinant Fusion Proteins / pharmacology*
  • Trichosanthin / genetics
  • Trichosanthin / metabolism*
  • Trichosanthin / pharmacology*

Substances

  • Antineoplastic Agents
  • Heparin-binding EGF-like Growth Factor
  • Peptides
  • Recombinant Fusion Proteins
  • Trichosanthin